Price T Rowe Associates Inc. MD Sells 28,705 Shares of Cabaletta Bio, Inc. (NASDAQ:CABA)

Price T Rowe Associates Inc. MD decreased its stake in shares of Cabaletta Bio, Inc. (NASDAQ:CABA) by 5.2% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 524,087 shares of the company’s stock after selling 28,705 shares during the period. Price T Rowe Associates Inc. MD owned 1.07% of Cabaletta Bio worth $1,191,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also bought and sold shares of CABA. Miller Financial Services LLC acquired a new position in shares of Cabaletta Bio in the fourth quarter valued at approximately $33,000. Avanza Fonder AB acquired a new position in Cabaletta Bio in the 4th quarter valued at $40,000. Intech Investment Management LLC lifted its holdings in shares of Cabaletta Bio by 42.2% during the fourth quarter. Intech Investment Management LLC now owns 20,203 shares of the company’s stock worth $46,000 after buying an additional 5,999 shares in the last quarter. Wells Fargo & Company MN boosted its position in shares of Cabaletta Bio by 67.3% in the fourth quarter. Wells Fargo & Company MN now owns 40,412 shares of the company’s stock valued at $92,000 after acquiring an additional 16,250 shares during the period. Finally, Stifel Financial Corp acquired a new position in shares of Cabaletta Bio in the fourth quarter valued at about $94,000.

Cabaletta Bio Stock Down 2.5 %

Shares of NASDAQ CABA opened at $1.18 on Friday. The company has a market capitalization of $59.88 million, a PE ratio of -0.55 and a beta of 2.72. The firm has a fifty day simple moving average of $1.40 and a 200 day simple moving average of $2.31. Cabaletta Bio, Inc. has a twelve month low of $0.99 and a twelve month high of $13.50.

Cabaletta Bio (NASDAQ:CABA) last announced its earnings results on Monday, March 31st. The company reported ($0.65) EPS for the quarter, meeting the consensus estimate of ($0.65). As a group, equities analysts expect that Cabaletta Bio, Inc. will post -2.34 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

CABA has been the topic of a number of recent research reports. Morgan Stanley lowered their price objective on Cabaletta Bio from $30.00 to $22.00 and set an “overweight” rating on the stock in a research note on Tuesday, April 1st. HC Wainwright reaffirmed a “buy” rating and set a $25.00 price objective on shares of Cabaletta Bio in a research report on Tuesday, April 1st. UBS Group decreased their target price on shares of Cabaletta Bio from $10.00 to $7.00 and set a “buy” rating on the stock in a report on Tuesday, April 1st. Wells Fargo & Company dropped their target price on shares of Cabaletta Bio from $6.00 to $3.00 and set an “equal weight” rating for the company in a research report on Tuesday, April 1st. Finally, Guggenheim reiterated a “buy” rating and set a $23.00 price target on shares of Cabaletta Bio in a research report on Tuesday, April 1st. One equities research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $21.00.

Cabaletta Bio Profile

Cabaletta Bio, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis.